Repository logo
  • Log In
    Log in via Symplectic to deposit your publication(s).
Repository logo
  • Communities & Collections
  • Research Outputs
  • Statistics
  • Log In
    Log in via Symplectic to deposit your publication(s).
  1. Home
  2. Faculty of Medicine
  3. National Heart and Lung Institute
  4. National Heart and Lung Institute
  5. Epinephrine infusion as an adjuvant treatment for breakthrough reactions during desensitization to methotrexate
 
  • Details
Epinephrine infusion as an adjuvant treatment for breakthrough reactions during desensitization to methotrexate
File(s)
PIIS1939455124000966.pdf (635.05 KB)
Published version
Author(s)
Toledo-Salinas, Carla
Mendoza-Hernandez, David Alejandro
Turner, Paul J
Type
Journal Article
Date Issued
2024-10
Date Acceptance
2024-08-15
Citation
The World Allergy Organization Journal, 2024, 17 (10)
URI
http://hdl.handle.net/10044/1/114076
URL
https://www.sciencedirect.com/science/article/pii/S1939455124000966?via%3Dihub
DOI
https://www.dx.doi.org/10.1016/j.waojou.2024.100965
ISSN
1939-4551
Publisher
Elsevier
Journal / Book Title
The World Allergy Organization Journal
Volume
17
Issue
10
Copyright Statement
© 2024 The Authors. Published by Elsevier Inc. on behalf of
World Allergy Organization. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
License URL
https://creativecommons.org/licenses/by/4.0/
Identifier
https://www.sciencedirect.com/science/article/pii/S1939455124000966?via%3Dihub
Publication Status
Published
Article Number
100965
Date Publish Online
2024-09-18
About
Spiral Depositing with Spiral Publishing with Spiral Symplectic
Contact us
Open access team Report an issue
Other Services
Scholarly Communications Library Services
logo

Imperial College London

South Kensington Campus

London SW7 2AZ, UK

tel: +44 (0)20 7589 5111

Accessibility Modern slavery statement Cookie Policy

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback